<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="Publisher" Owner="NLM">        <PMID Version="1">30383154</PMID>        <DateRevised>            <Year>2018</Year>            <Month>11</Month>            <Day>01</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">2168-6173</ISSN>                <JournalIssue CitedMedium="Internet">                    <PubDate>                        <Year>2018</Year>                        <Month>Nov</Month>                        <Day>01</Day>                    </PubDate>                </JournalIssue>                <Title>JAMA ophthalmology</Title>                <ISOAbbreviation>JAMA Ophthalmol</ISOAbbreviation>            </Journal>            <ArticleTitle>Association of Cancer Immunotherapy With Acute Macular Neuroretinopathy and Diffuse Retinal Venulitis.</ArticleTitle>            <ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaophthalmol.2018.5191</ELocationID>            <Abstract>                <AbstractText Label="Importance" NlmCategory="UNASSIGNED">Checkpoint inhibition in cancer immunotherapy related to T-cell-driven mechanisms of action associated with acute macular neuroretinopathy (AMN) and diffuse retinal venulitis, an adverse event not previously described, is reported here.</AbstractText>                <AbstractText Label="Objective" NlmCategory="UNASSIGNED">To describe 2 patients who developed ophthalmologic events after treatment with the programmed death 1 axis inhibitor, atezolizumab.</AbstractText>                <AbstractText Label="Design, Setting, and Participants" NlmCategory="UNASSIGNED">Retrospective review of 2 patients treated with atezolizumab for metastatic breast cancer and colon cancer, respectively, who presented with AMN and diffuse retinal venulitis conducted at 2 tertiary medical centers.</AbstractText>                <AbstractText Label="Main Outcomes and Measures" NlmCategory="UNASSIGNED">Multimodal imaging including near infrared, optical coherence tomography, and fluorescein angiography were used to characterize retinal vascular abnormalities.</AbstractText>                <AbstractText Label="Results" NlmCategory="UNASSIGNED">Based on optical coherence tomography and multimodal imaging findings, the clinical diagnosis of AMN associated with diffuse retinal venulitis was made in these 2 patients receiving atezolizumab.</AbstractText>                <AbstractText Label="Conclusions and Relevance" NlmCategory="UNASSIGNED">While only 2 cases of patients receiving the programmed death ligand 1 inhibitor atezolizumab who experienced AMN and diffuse retinal venulitis are described here, these findings suggest that patients receiving programmed death 1 axis inhibitor therapies may need to be monitored for unexpected immune-related ocular toxicity including abnormalities of the microvasculature and large retinal vessels. Further studies might investigate the potential mechanisms of retinal vascular changes associated with these therapies.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Emens</LastName>                    <ForeName>Leisha A</ForeName>                    <Initials>LA</Initials>                    <AffiliationInfo>                        <Affiliation>Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University School of Medicine, Baltimore, Maryland.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>now with University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh, Pennsylvania.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Davis</LastName>                    <ForeName>S Lindsey</ForeName>                    <Initials>SL</Initials>                    <AffiliationInfo>                        <Affiliation>University of Colorado Cancer Center, Aurora.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Oliver</LastName>                    <ForeName>Scott C N</ForeName>                    <Initials>SCN</Initials>                    <AffiliationInfo>                        <Affiliation>University of Colorado Eye Center, University of Colorado School of Medicine, Aurora.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Lieu</LastName>                    <ForeName>Christopher H</ForeName>                    <Initials>CH</Initials>                    <AffiliationInfo>                        <Affiliation>University of Colorado Cancer Center, Aurora.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Reddy</LastName>                    <ForeName>Ashvini</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Solomon</LastName>                    <ForeName>Sharon</ForeName>                    <Initials>S</Initials>                    <AffiliationInfo>                        <Affiliation>Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>He</LastName>                    <ForeName>Lingmin</ForeName>                    <Initials>L</Initials>                    <AffiliationInfo>                        <Affiliation>Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Morley</LastName>                    <ForeName>Roland</ForeName>                    <Initials>R</Initials>                    <AffiliationInfo>                        <Affiliation>Genentech Inc, South San Francisco, California.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Fass√≤</LastName>                    <ForeName>Marcella</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>Genentech Inc, South San Francisco, California.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Pirzkall</LastName>                    <ForeName>Andrea</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>Genentech Inc, South San Francisco, California.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Patel</LastName>                    <ForeName>Hina</ForeName>                    <Initials>H</Initials>                    <AffiliationInfo>                        <Affiliation>Genentech Inc, South San Francisco, California.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>O'Hear</LastName>                    <ForeName>Carol</ForeName>                    <Initials>C</Initials>                    <AffiliationInfo>                        <Affiliation>Genentech Inc, South San Francisco, California.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Ferrara</LastName>                    <ForeName>Daniela</ForeName>                    <Initials>D</Initials>                    <AffiliationInfo>                        <Affiliation>Genentech Inc, South San Francisco, California.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>11</Month>                <Day>01</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>United States</Country>            <MedlineTA>JAMA Ophthalmol</MedlineTA>            <NlmUniqueID>101589539</NlmUniqueID>            <ISSNLinking>2168-6165</ISSNLinking>        </MedlineJournalInfo>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>11</Month>                <Day>2</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>11</Month>                <Day>2</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>11</Month>                <Day>2</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>aheadofprint</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30383154</ArticleId>            <ArticleId IdType="pii">2712694</ArticleId>            <ArticleId IdType="doi">10.1001/jamaophthalmol.2018.5191</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>